|
|||
![]() |
|||
2017-08-15 08:00:53 CEST 2017-08-15 08:00:53 CEST Revenio Group Oyj - Managers' transactionsRevenio Group Corporation: Managers' transactionsRevenio Group Corporation, Managers' transactions, August 15, 2017 at 9:00 EET Revenio Group Corporation: Managers' transactions Revenio Group Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Joensuun Kauppa ja Kone Oy Position: Closely associated person (X) Legal person (1):Closely associated person Name: Kakkonen, Kyösti Position: Member of the Board Issuer: Revenio Group Oyj LEI: 743700l27E0FWSXLKK04 Notification type: INITIAL NOTIFICATION Reference number: 743700l27E0FWSXLKK04_20170814124020_1 ____________________________________________ Transaction date: 2017-08-11 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009010912 Nature of the transaction: ACQUISITION Transaction Details (1): Volume: 1200 Unit price: 35,70700 EUR Aggregated transactions (1): Volume: 1200 Volume weighted average price: 35.70700 EUR For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932 Distribution: Nasdaq Helsinki www.revenio.fi The Revenio Group in brief Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow- up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process. In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit for continuing operations standing at 30.1%. Revenio Group Corporation is listed on Nasdaq Helsinki. [] |
|||
|